Boehringer Ingelheim Partners With MEDS To Expand Access to Life-Saving Medications for Kenyans

By Isaac OGANGA

Boehringer Ingelheim, a global leader in innovative healthcare solutions, has partnered with Mission for Essential Drugs and Supplies (MEDS) to strengthen its ‘Access to Healthcare’ program in Kenya.

The collaboration aims to provide affordable, life-saving medications to patients with type 2 diabetes and hypertension, while enhancing local healthcare infrastructure.

Access to Healthcare program was launched in September 2022, has already made significant strides by engaging over 200 physicians, enrolling 1,500 patients, and partnering with 15 healthcare facilities across Kenya.

The initiative offers subsidized medications and emphasizes patient adherence to treatment, addressing the growing burden of non-communicable diseases (NCDs) in the country. NCDs currently account for 27% of all deaths in Kenya.

Derek O’Leary, Regional Managing Director at Boehringer Ingelheim, emphasized, “At Boehringer Ingelheim, we believe that access to quality healthcare is a fundamental right. This partnership with MEDS is a game-changer in our mission to bridge the gap for underserved communities in Kenya. Together, we are delivering hope and building a more resilient healthcare system for future generations.”

The partnership also includes community awareness campaigns to raise awareness about type 2 diabetes and hypertension, promoting early diagnosis and treatment.

This collaboration will enable us to provide the latest innovations in treatment to eligible patients, improving their health outcomes and preserving their quality of life – Dr. Stephen Kigera of MEDS stated.

As part of its Sustainable Development for Generations framework, Boehringer Ingelheim aims to expand access to healthcare for 50 million people in underserved communities by 2030.